Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. It also provides Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; PYLARIFY AI, an medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer; and flurpiridaz used to assess blood flow to the heart. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy to patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent for Tau tangles in Alzheimer's disease; LNTH-2401, a novel radiodiagnostic targeting the gastrin-releasing peptide receptor; LNTH-2402; LNTH-2403; LNTH-2404; and LNTH-1363S, an fibroblast activation protein, alpha, copper-64 labeled PET imaging agent. It has collaboration agreements with GE Healthcare; POINT; Regeneron; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

Lantheus Holdings Inc.

In a report released today, Matthew Taylor from Jefferies maintained a Buy rating on Lantheus, with a price target of $105.00. Taylor covers the He...

Market Cap	$3.64B	P/E Ratio	14.36
52W High	$111.29	52W Low	$47.25
Div Yield	N/A	Payout Ratio	0.0%
EPS Growth 3Y	84.3%	52W Position	30.2%
Overall Score	75	Value Score	80
Quality Score	57	Technical Score	90

EPS Current Est	$4.64	EPS Next Est	$4.67
EPS Growth Est	+0.6%	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	LNTH	$66.62	+5.58%	1.55M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	LNTH	$66.62	+5.6%	1.55M
3
4
5
6

LNTH

LNTH

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Lantheus Holdings Inc. Data in Excel

Get Lantheus Holdings Inc. Data in Excel